NEW YORK (GenomeWeb News) April 28 - Christopher Becker has been promoted to vice president, chemistry at SurroMed, and William Leschensky has been promoted to president, intellectual property.
Becker joined SurroMed as director of chemistry in 2001, after serving as senior director of proteomic technology at Thermo Electron, and previously, as a staff scientist at SRI. He received his PhD in chemistry at UC Berkeley. Leschensky has been director of intellectual property at SurroMed since 2000, and has also been associate general counsel. Before joining SurroMed, he was an associate at the law firm Fish & Neave. He received his MD from the University of Illinois and a law degree from Harvard Law School.
Rob Arnold has been named president and COO of Geospiza, the Seattle sequencing and IT company said Tuesday.
Arnold was the co-founder and CEO of ST Labs, a software firm that he sold to Data Dimensions (now LionBridge), after it grew to a staff of 250. He was subsequently VP of the test center division of Data Dimensions, and then CEO and chairman of Crossport Systems, a provider of broadband security solutions. He then directed Crossport's sale to Lineo, which is now a division of Motorola. He currently leads ArrayBio, a special interest group for bio-IT sector in Seattle, and is a member of the steering committed for the Bio21 initiative, a proposal to invest public money in Washington State's biotech industry.
NaPro Biotherapeutics has formed a new oncology scientific advisory board, and has named Paul Bunn chairman, and members including Gail Eckhardt, Eric Rowinsky, and Daniel Von Hoff.
Bunn is the director of the University of Colorado Cancer Center, and previously served as president of the American Society of Clinical Oncology and chairman of the US Food and Drug Administration's Oncology Drugs Advisory Committee. Bunn received his MD from Cornell University Medical College.
Eckhardt is a professor of medicine and the director of the developmental therapeutics and GI malignancies programs at the University of Colorado Health Science Center in Denver. She has previously served as associate director of clinical research, cancer therapy and the research center at the Institute for Drug Development in San Antonio, Texas. She received an MD from the University of Texas Medical Branch in Galveston.
Rowinsky is the director of the Institute for Drug Development, Cancer Therapy and Research Center and clinical professor of medicine at the University of Texas Health Science Center at San Antonio. He received his MD from the Vanderbilt School of Medicine.
Von Hoff is professor of medicine, pathology, molecular and cellular biology and the director of the Arizona Health Sciences Center's cancer therapeutics program. He is also director of translational research at the Translational Genomics Research Institute, and Chief Scientific Officer for US Oncology, and a founder of ILEX Oncology. Von Hoff received his M.D. from Columbia University.
NaPro, of Boulder, Colo., is seeking diagnostic and therapeutic applications for its gene editing technology in cancer and hereditary disease
Alan Carter has been appointed vice president, worldwide sales of BioTrove, the company said Monday. Carter comes to the Woburn, Mass., company from Gene Logic, where he was director of business development.
Prior to Gene Logic, Carter has served as sales director for Celera Genomics, vice president of sales and marketing for Lark Technologies, and western regional manager, Applied Biosystems where he served as. Prior to joining ABI, he was a western regional manager with Polygen and a sales representative with Perkin Elmer. He holds a BS in Chemistry from Virginia Tech.
Mark Rogers has been appointed chairman of the board of directors of Aptamera, the Louisville, Ky., oncology drug development company said Monday.
Rogers has been CEO of Duke University Hospital and Health Network and a professor and associate dean at Johns Hopkins School of Medicine. He has also worked in Venture Capital and chaired firms including Genta, Adherex Technologies, and PolaRx Biopharmaceuticals.
Genaera has named ten ophthalmic and retinal specialists to its ophthalmic advisory board. These include Susan Bressler, professor of Opthalmology at Johns Hopkins University School of Medicine; Charles Garcia, professor of Opthalmology and Visual Science at the University of Texas Health Science Center in Houston; Glenn Jaffe, professor of ophthalmology at Duke
University Eye Center; Michael Klein, professor, Casey Eye Institute-Oregon Health & Science University; Hugo Quiroz-Mercado, MD, Chief of the Retina Service, Chief of Experimental Surgery Laboratory and the Coordinator of the Research Committee at the Asociacion Para Evitar la Ceguera en Mexico; Gholam A. Peyman, professor of ophthalmology, co-director of vitreo-retinal service, Tulane University School of Medicine; Lawrence Rand, retinal specialist Waban, Massachusetts; Carl Regillo, professor of ophthalmology, Thomas Jefferson University, School of Medicine; Jack Owens Sipperley, senior partner, Retinal Consultants of Arizona; and
Edgar Thomas, Retina-Vitreous Associates.
James Beery has been appointed to the board of directors of Orchid BioSciences, the company said Friday.
Beery is senior of counsel at Covington & Burling, which he joined in 2002. Before that, he was
senior vice president and general counsel of GlaxoSmithKline. Over two decades, he has served in leading law firms, and before that served as a captain in the US Marine Corps in Vietnam.. He holds a JD from Stanford Law School, and an undergraduate degree from Harvard College.
Andrew Fire and Anthony Pawson have been elected to the US National Academy of Sciences, in a session last week when the academy elected 72 new members.
Fire, a professor of pathology and genetics at Stanford University School of Medicine, made early discoveries in the field of RNA interference.
Pawson, an international research scholar at Howard Hughes Medical Institute and a University Professor in the department of medical genetics and microbiology at University of Toronto, has made major advances in signal transduction within the cell.